Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...
Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to Buy while trimming the target price to $58 from $82.
Shares of vaccine makers lost ground Thursday, hit by news that President-elect Donald Trump was naming vaccine skeptic and ...
The selection of vaccine sceptic Robert F Kennedy Jr by US President-elect Donald Trump to head the Department of Health and ...
Vaccine stocks have struggled since RFK Jr.'s appointment to health secretary, with Moderna and Pfizer seeing the deepest ...
Shares of Moderna Inc. (NASDAQ: MRNA) are trading lower after President-elect Donald Trump nominated Robert F. Kennedy Jr. to ...
1d
Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...
4don MSN
Shares of COVID vaccine manufacturers Moderna and Pfizer fell early Friday morning, down 4% and 4.3% respectively.
With the help of TBWA\Chiat\Day New York, pharma giant Moderna is demystifying mRNA science for the average consumer. This ...
Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback